| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 3.36 +11.31% on 04/07/25 |
Period Open: 4.07
| 4.07 -8.11% on 03/25/25 | -0.33 (-8.11%) since 03/21/25 |
| 3-Month | 3.36 +11.31% on 04/07/25 |
Period Open: 3.94
| 4.15 -9.88% on 03/07/25 | -0.20 (-5.08%) since 01/22/25 |
| 52-Week | 3.36 +11.31% on 04/07/25 |
Period Open: 3.73
| 4.15 -9.88% on 03/07/25 | +0.01 (+0.27%) since 04/22/24 |
Western Asset High Income Opportunity Fund Inc. (NYSE: HIO) today announced the financial position of the Fund as of December 31, 2022.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of December 2022, January and February 2023.
Western Asset High Income Opportunity Fund Inc. (NYSE: HIO) today announced the financial position of the Fund as of June 30, 2022.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of September, October, and November 2022.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of June, July, and August 2022.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of March, April and May 2022.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of December 2021, January and February 2022.
Western Asset High Income Opportunity Fund Inc. (NYSE: HIO) today announced the financial position of the Fund as of June 30, 2021.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of September, October, and November 2021.
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of June, July, and August 2021.
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Message volume on Stocktwits has surged by over 1,200% since the beginning of the year, reflecting growing interest.
Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.
/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Bio-Techne has underperformed the biotechnology industry over the past year, but analysts are highly optimistic about the stock’s prospects.
The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.
This milestone marks the first achievement since the partnership began in May, with the potential for Novavax to earn up to $300 million in additional milestones.
An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.
Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.
he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Message volume on Stocktwits has surged by over 1,200% since the beginning of the year, reflecting growing interest.
Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.
Bio-Techne has underperformed the biotechnology industry over the past year, but analysts are highly optimistic about the stock’s prospects.
The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.
This milestone marks the first achievement since the partnership began in May, with the potential for Novavax to earn up to $300 million in additional milestones.
An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.
Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.
he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Message volume on Stocktwits has surged by over 1,200% since the beginning of the year, reflecting growing interest.
Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.
Bio-Techne has underperformed the biotechnology industry over the past year, but analysts are highly optimistic about the stock’s prospects.
The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.
This milestone marks the first achievement since the partnership began in May, with the potential for Novavax to earn up to $300 million in additional milestones.
An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.
Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.
he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.
| Date | Value |
|---|---|
| 04/23/25 | $0.0360 |
| 03/24/25 | $0.0360 |
| 02/21/25 | $0.0360 |
| 01/24/25 | $0.0360 |
| 12/23/24 | $0.0360 |
| 11/21/24 | $0.0360 |
| 10/24/24 | $0.0360 |
| 09/23/24 | $0.0360 |
| 08/23/24 | $0.0360 |
| 07/24/24 | $0.0360 |
| 06/21/24 | $0.0360 |
| 05/22/24 | $0.0360 |
| 04/22/24 | $0.0360 |
| 03/20/24 | $0.0360 |
| 02/21/24 | $0.0360 |
| 01/23/24 | $0.0360 |
| 12/20/23 | $0.0360 |
| 11/21/23 | $0.0360 |
| 10/23/23 | $0.0360 |
| 09/21/23 | $0.0360 |
| 08/23/23 | $0.0300 |
| 07/21/23 | $0.0300 |
| 06/22/23 | $0.0300 |
| 05/22/23 | $0.0300 |
